Literature DB >> 8695850

Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.

P P Cheung1, H Xu, M M McLaughlin, F A Ghazaleh, G P Livi, R W Colman.   

Abstract

Cyclic adenosine monophosphate (cAMP) is an important modulator of platelet responses to agonists. Cyclic nucleotide phosphodiesterase (PDE) controls intracellular cAMP concentrations by hydrolyzing it to AMP. The major PDE activity in platelets is PDE3A (cyclic guanosine monophosphate [cGMP]-inhibited PDE). To obtain structural information on platelet PDE3A, we cloned the enzyme cDNA from a human erythroleukemia cell (HEL) library since the cell line expresses many platelet proteins. This clone consists of 87% of the full-length human myocardial PDE3A cDNA, spanning from nucleotides 456 to 4606, and is identical in sequence. The nucleotide coding for the N terminal 179 amino acid sequence (nt 1-536) as well as four other cDNAs (nt 1459-1632, nt 1765-1986, nt 2152-2538, and nt 2978-3375) obtained by RT-PCR of platelet RNA are also identical to the myocardial sequences, indicating that the HEL, myocardial, and platelet PDE3As are the same. Northern blot analysis of HEL cell RNA detected two mRNAs of 7.5 and 4.4 kb. Four new deletion mutants are reported. PDE 3A delta 1 and PDE 3A delta 2, encoding amino acids 665 to 1141 and amino acids 679 to 1141, respectively, were expressed in a PDE-deficient yeast. They displayed PDE activities of 172 and 79 pmol/mg/min, respectively. PDE 3A delta 3 and PDE 3A delta 4, encoding amino acids 686 to 1141 and 700 to 1141, had no detectable PDE activity. All mutant proteins were expressed as determined by Western blot analysis. These findings localize the PDE3A catalytic domain to within amino acid residues 679 to 1141.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695850

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

Authors:  Y H Choi; D Ekholm; J Krall; F Ahmad; E Degerman; V C Manganiello; M A Movsesian
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

2.  Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.

Authors:  K M Tang; E K Jang; R J Haslam
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

3.  Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.

Authors:  W Zhang; H Ke; A P Tretiakova; B Jameson; R W Colman
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

Review 4.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

5.  Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

Authors:  Wei Zhang; Robert W Colman
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

6.  A new nonhydrolyzable reactive cGMP analogue, (Rp)-guanosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate, which targets the cGMP binding site of human platelet PDE3A.

Authors:  Su H Hung; Andy H Liu; Robin A Pixley; Penelope Francis; LaTeeka D Williams; Christopher M Matsko; Karine D Barnes; Sharmila Sivendran; Roberta F Colman; Robert W Colman
Journal:  Bioorg Chem       Date:  2008-04-03       Impact factor: 5.275

7.  Use of the KlADH3 promoter for the quantitative production of the murine PDE5A isoforms in the yeast Kluyveromyces lactis.

Authors:  Silvia Cardarelli; Mauro Giorgi; Fabio Naro; Francesco Malatesta; Stefano Biagioni; Michele Saliola
Journal:  Microb Cell Fact       Date:  2017-09-22       Impact factor: 5.328

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.